pharma · SBRT · Covid19 · GRTX
Kailera Therapeutics
Galera Therapeutics
Kailera Therapeutics is a pharma organization headquartered in Waltham, USA. It trades on NYSE under ticker GRTX. Primary therapeutic focus areas include SBRT, Covid19, Head and Neck Cancer, Oral Mucositis, Esophagitis.
Waltham, Massachusetts, United States HQ
2024 Founded
153 Employees
Public company Type
GRTX · NYSE Ticker
Company details
- Status
- Public
- HQ
- Waltham, Massachusetts, United States
- Founded
- 2024
- Employees
- 153
- Programs
- 17
- Drugs
- 7
- Patents
- 23
GC4419 (avasopasem manganese)
Phase 2 · small molecule · Esophagitis
GC4419 (avasopasem manganese) for Esophagitis is a Phase 2 program (small_molecule) at Galera Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code GTI-4419-203
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Galera Therapeutics
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Esophagitis
- Status
- terminated
- Trials
- 1